In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: October 2009

Executive Summary

Sanofi-Aventis was the standout in pharma alliances, penning three of the big deals, which together were worth over $1 billion in potential deal value. Onyx's buy of cancer and immunology biotech Proteolix topped the M&A chart at $851 million. In devices, notable was Kimberly-Clark, which followed up last month's Baylis acquisition with another in pain management--I-Flow, for $309 million, over twice that company's sales. Almost 40% of pharma financing came from Talecris' $600 million notes offering. And fundraising for the device industry was boosted by an $88 million IPO completed by AGA Medical Holdings, and a $55 million Series B from TransEnterix.

You may also be interested in...



Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies

Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.

Could A COVID-19 Vaccine Gain EUA Without Sponsor Cooperation?

The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.

There’s No Need To Include Off-Label Use In Labeling, FDA Says In Proposed Rule

After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel